OMC
ADMS

Old Mission Capital’s Adamas Pharmaceuticals ADMS Stock Holding History

Old Mission Capital’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-70,400
Closed -$180K – 668
2020
Q2 		$180K Buy
+70,400
New +$207K 0.01% 391

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Old Mission Capital's ADMS Position: Q3 2020 in Review

Old Mission Capital sold out of Adamas Pharmaceuticals (ADMS) in Q3 2020, closing a stake of 70,400 shares — an estimated $180K sold.

Old Mission Capital first reported a position in ADMS in Q2 2020 and held it in 1 quarter. The position peaked at $180K in Q2 2020. 63 funds tracked by Wall St. Rank hold ADMS as of Q3 2020.

  • Old Mission Capital reported no remaining Adamas Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Old Mission Capital sold 70,400 Adamas Pharmaceuticals shares in Q3 2020, an estimated $180K.
  • Old Mission Capital first reported a position in Adamas Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Old Mission Capital's Adamas Pharmaceuticals position peaked at $180K in Q2 2020.
  • 63 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2020.

Based on Old Mission Capital's 13F filing for Q3 2020, filed 16 Nov 2020.